Conclusion
The analytical method for the determination of NT in plasma here proved to be highly sensitive and specific. The method has been available for controlled trials and in clinical practice.
Concerning the effect of TAs during long-term treatment our investigations have shed light on unclarified dosage factors of great importance for the elucidation of the possible prophylactic effect of the TAs.
The plasma level determination of NT has simplified the discrimination between true pharmacological side effects, which call for reduction of dosage, and placebo or depressive symptoms. In patients not responding to a certain dosage, a plasma level determination will indicate whether the dosage should be raised or rather lowered. Our results prove this point, and we think we have a reasonable basis for the hypothesis that both a lower and an upper limit for therapeutic effect exist.
Next, those patients who do not recover, even on optimal plasma levels, can be identified and receive alternative treatment, instead of undue prolongation of an ineffective therapy on changing doses.
Whether a relationship between the plasma concentration and effects will hold also for other TAs remains to be investigated. It is not possible, at the present stage of knowledge, to extrapolate from one drug to another. It should also be pointed out that the curvilinear relationship between plasma level and therapeutic effect has only been demonstrated in patients with endogenous depressions and cannot be generalized to other depressive states without further trials. Techniques are now available for measuring many of the anticonvulsants in clinical use, but I will confine my discussion to a consideration of diphenylhydantoin (DPH), for which the most information and experience has accumulated.
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Although the drug has been in use since 1938 (Merritt & Putnam) , it was not until the late 1950s and early 1960s that successful attempts were made to measure serum levels, principally in Denmark. With the more recent development of gas chromatographic techniques there has been widespread interest in their possible clinical application (see Buchthal & Lennox-Buchthal 1972) .
Factors Affecting Serum Levels ofDPH
As for most drugs, it soon became apparent that for any given dose of DPH there is a wide variation in serum levels between individual patients:
(1) The mean serum half life of DPH is 22 hours, but a wide range (7-42 hours) has been noted by various authors, as the half life increases linearly with the serum level (Houghton & Richens 1974) .
(2) With oral medication a steady state level of DPH is achieved in 2-13 days, depending on the daily dose (Svensmark et al. 1960 , Loeser 1961 . It is usually unnecessary to administer the drug more than twice daily; indeed, steady state levels throughout the day have been reported with a single daily dose (Haerer & Buchanan 1972 , Strandjord & Johannessen 1972 .
(3) For any individual patient the relationship between dose and serum level is not a linear one, as the latter will rise increasingly steeply as the dose is steadily increased (Bochner et al. 1972a ). Within the optimum range of 10-20,tg/ml small incremental changes of dose may lead to a relatively large rise or fall in serum level, perhaps precipitating toxicity or loss of seizure control.
(4) The capacity to metabolize (parahydroxylate) the drug varies with age, especially in children, in whom relatively larger doses (in terms of body weight) are required to achieve serum levels comparable to adult patients (Svensmark & Buchthal 1963 , Jalling et al. 1970 ).
(5) There has been relatively little investigation of the pharmacogenetics of DPH, but the family studies of Kutt, Wolk, Sherman & McDowell (1964) suggest that it may be important. A few patients develop very high serum levels of the drug on modest doses (e.g. 300 mg daily), possibly because of a genetically determined incapacity to adequately hydroxylate this dose (Lascelles et al. 1970 ). (6) Studies in Denmark (Lund et al. 1964 ) and this country (Gibberd et al. 1970) have confirmed that many patients fail to take the prescribed dose of the drug. (7) Variation in absorption, metabolism or excretion of the drug due to gastrointestinal, hepatic or renal disease, has been identified in some patients (Kutt, Winters, Sherman & McDowell 1964 , Letteri et al. 1971 , and this constitutes a serious problem for many epileptic patients who have to take the drug for most of their life. (9) DPH is 80-90 % protein bound. As the biological activity of the drug depends on its free concentration and as the degree of protein binding may be altered, for example, by other drugs or in uremia (Reidenberg et al. 1971 ), it may be more appropriate in some circumstances to measure the free rather than the total drug concentration (Booker & Darcey 1973) . (10) Variation in the formulation of DPH capsules may lead to alteration in the bioavailability of the drug as, for example, when an outbreak of DPH toxicity occurred in Australia when the excipient was changed from calcium sulphate to lactose (Bochner et al. 1972b) .
Relation ofSerum to Central Nervous System Levels ofDPH For meaningful interpretation of serum levels, it is important to know that they reflect levels in the nervous system. Certainly there is a good correlation between serum and cerebrospinal fluid levels (which are equivalent to the unbound fraction in serum) (Triedman etal. 1960, Reynolds (Sherwin, Eisen & Sokolowski 1973) and studies of resected human temporal lobe specimens (Vajda et al. 1974) suggest that there is also a good correlation with brain levels.
Relation ofSerum Levels to Seizure Control It is apparent that there is no clear relationship applicable to all patients. Buchthal et al. (1960) , who found that 86% of patients with levels above 15 ,ug/ml were significantly improved whereas this was true in only 25 % of those with levels below 10 ,ug/ml, suggested that the optimal 'therapeutic' range is 10-20 ,g/ml. Although this is a useful practical objective it is already clear that many patients within this range remain uncontrolled, and others are controlled with levels below 10 ,ug/ml. The severity of the underlying seizure disorder in individual patients is an important factor in determining drug requirements and response to therapy. In large series of patients there may be no significant difference in DPH levels between controlled and uncontrolled epileptics, or the latter group may have relatively higher levels due to the administration of greater quantities of the drug in an unsuccessful attempt to control severe epilepsy completely (Buchanan & Allan 1971, Travers et al. 1972 , Borofsky et al. 1972 ). However, Lund (1973) found that patients who had no seizures in the previous two months had significantly higher DPH levels than those with continuing attacks, although the mean dose of the drug was similar in the two groups. Paradoxically, toxic levels of DPH may sometimes aggravate seizures (Lascelles et al. 1970) .
The critical question is to what extent patients with continuing seizures and low serum DPH levels will be improved by increasing the drug level into the 10-20 ,ug/ml range, and this has not yet been satisfactorily assessed in a controlled manner with adequate follow up. The answer to this and other questions of the value of serum DPH levels will not be available until long-term studies have been completed, but a two-year study demonstrating the value of serum ethosuximide levels in improving petit mal control provides some grounds for optimism (Sherwin, Robb & Lechter 1973) .
Relation ofSerum Levels to Toxicity Earlier reports of a very precise relationship between acute toxic effects and serum levels (Kutt, Winters, Kokenge & McDowell 1964) have not been confirmed and again considerable individual variation is apparent. Above 15-20 ,ug/ml there is a rising prevalence of clearly recognizable toxic effects such as nystagmus, ataxia and confusion, but some patients seem to tolerate high levels without obvious immediate (Buchthal et al. 1960 ). However, the problem is occasionally complicated by unusual neurological or psychiatric manifestations of toxicity, sometimes in the absence of the more classical signs, especially if the patient is already brain damaged (Reynolds 1970 , Glaser 1972 , Reynolds & Travers 1974 ). An inverse relationship between DPH (and phenobarbitone) and folate levels has been reported ) but some of the insidious chronic effects of the drugs are not necessarily clearly related to serum levels, and duration of therapy may be equally, if not more, important (Reynolds 1975) .
Conclusion
Although the place ofregular monitoring ofserum DPH levels has yet to be evaluated by long-term studies, the value of occasional measurements in individual patients who are difficult management problems has been emphasized by many. Table 2 lists some of the clinical situations in which such measurements may be helpful: (1) For any patient with continuing seizures, it is useful to make sure that an optimum serum level has been achieved before considering the addition of or substitution by another drug. (2) Serum levels will also indicate which drug may be appropriately reduced if a patient on multiple drug therapy presents with signs of toxicity. (3) As DPH toxicity may sometimes present with a variety of atypical neurological or psychiatric syndromes, the serum level should be measured in any patient on the drug presenting with new neuropsychiatric symptoms.
With the increasing availability of facilities for measuring serum levels of DPH and other anticonvulsants, there is now much less risk of under or overdosage with these drugs. This is particularly important in patients who may have to take anticonvulsant therapy for many years of their life. Studies currently in progress will define more precisely the indications for and frequency of such measurements, and will also assess whether this has any impact on the long-term prognosis of epilepsy.
